Literature DB >> 8645244

Identification of three separate binding sites on SHK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain.

M W Pennington1, V M Mahnir, D S Krafte, I Zaydenberg, M E Byrnes, I Khaytin, K Crowley, W R Kem.   

Abstract

Eighteen synthetic analogs of ShK toxin, a thirty-five residue K channel blocker derived from the sea anemone Stichodactyla helianthus, were prepared in order to identify functionally important residues. CD spectra of sixteen of the analogs were virtually identical with the spectrum of wild-type toxin, indicating that the conformations were not affected by the substitutions. A conserved residue, Lys22, is essential for ShK binding to rat brain K channels which are primarily of the Kv1.2 type. However, a cationic side chain at position 22 is not essential for binding to the human Jurkat T-lymphocyte Kv1.3 channel. While decreasing bulkiness at this position affected toxin affinity for the brain K channels, increasing bulkiness decreased toxin affinity for both brain and lymphocyte K channels. In contrast to the rat brain channels, ShK binding to Kv1.3 was sensitive to substitution at Lys9 and Arg11.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645244     DOI: 10.1006/bbrc.1996.0297

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Design and synthesis of type-III mimetics of ShK toxin.

Authors:  Jonathan B Baell; Andrew J Harvey; Raymond S Norton
Journal:  J Comput Aided Mol Des       Date:  2002-04       Impact factor: 3.686

2.  Recombinant production and solution structure of PcTx1, the specific peptide inhibitor of ASIC1a proton-gated cation channels.

Authors:  Pierre Escoubas; Cédric Bernard; Gérard Lambeau; Michel Lazdunski; Hervé Darbon
Journal:  Protein Sci       Date:  2003-07       Impact factor: 6.725

3.  Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.

Authors:  M W Pennington; C Beeton; C A Galea; B J Smith; V Chi; K P Monaghan; A Garcia; S Rangaraju; A Giuffrida; D Plank; G Crossley; D Nugent; I Khaytin; Y Lefievre; I Peshenko; C Dixon; S Chauhan; A Orzel; T Inoue; X Hu; R V Moore; R S Norton; K G Chandy
Journal:  Mol Pharmacol       Date:  2009-01-02       Impact factor: 4.436

4.  Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Authors:  Christine Beeton; Michael W Pennington; Heike Wulff; Satendra Singh; Daniel Nugent; George Crossley; Ilya Khaytin; Peter A Calabresi; Chao-Yin Chen; George A Gutman; K George Chandy
Journal:  Mol Pharmacol       Date:  2005-01-21       Impact factor: 4.436

Review 5.  Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Authors:  Christine Beeton; Michael W Pennington; Raymond S Norton
Journal:  Inflamm Allergy Drug Targets       Date:  2011-10

6.  Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria.

Authors:  Shih Chieh Chang; Charles A Galea; Eleanor W W Leung; Rajeev B Tajhya; Christine Beeton; Michael W Pennington; Raymond S Norton
Journal:  Toxicon       Date:  2012-05-31       Impact factor: 3.033

7.  A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.

Authors:  Michael W Pennington; M Harunur Rashid; Rajeev B Tajhya; Christine Beeton; Serdar Kuyucak; Raymond S Norton
Journal:  FEBS Lett       Date:  2012-10-09       Impact factor: 4.124

8.  Screening and cDNA cloning of Kv1 potassium channel toxins in sea anemones.

Authors:  Yoshikazu Yamaguchi; Yuichi Hasegawa; Tomohiro Honma; Yuji Nagashima; Kazuo Shiomi
Journal:  Mar Drugs       Date:  2010-12-02       Impact factor: 5.118

Review 9.  Peptide toxins in sea anemones: structural and functional aspects.

Authors:  Tomohiro Honma; Kazuo Shiomi
Journal:  Mar Biotechnol (NY)       Date:  2006-01-01       Impact factor: 3.619

10.  Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.

Authors:  Michael W Pennington; Shih Chieh Chang; Satendra Chauhan; Redwan Huq; Rajeev B Tajhya; Sandeep Chhabra; Raymond S Norton; Christine Beeton
Journal:  Mar Drugs       Date:  2015-01-16       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.